Tafamidis Meglumine

• CAT Number: I014697
• CAS Number: 951395-08-7
• Molecular Formula: C21H24Cl2N2O8
• Molecular Weight: 503.33
• Purity: 98%
• Synonyms: Tafamidis meglumine; Fx 1006A; Fx-1006A; Fx1006A; PF-06291826; PF 06291826; PF06291826;;(2R,3R,4R,5S)-6-(methylamino)hexane-1,2,3,4,5-pentaol 2-(3,5-dichlorophenyl)benzo[d]oxazole-6-carboxylic acid
• Target: Transthyretin (TTR)
• Target Protein: P02766
• Solubility: Soluble in DMSO
• Appearance: Solid
• Storage: Dry, dark and at 2 - 8 °C for six months or -20°C for two years.
• IC50: EC50: 2.7-3.2 μM (TTR)
• IUPAC Name: 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid;(2R,3R,4R,5S)-6-(methylamino)hexane-1,2,3,4,5-pentol
• InChI: InChI=1S/C14H7Cl2NO3.C7H17NO5/c15-9-3-8(4-10(16)6-9)13-17-11-2-1-7(14(18)19)5-12(11)20-13;1-8-2-4(10)6(12)7(13)5(11)3-9/h1-6H,(H,18,19);4-13H,2-3H2,1H3/t;4-,5+,6+,7+/m.0/s1
• InChIKey: DQJDBUPLRMRBAB-WZTVWXICSA-N
• SMILES: CNC[C@@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O.C1=CC2=C(C=C1C(=O)O)OC(=N2)C3=CC(=CC(=C3)Cl)Cl

Tafamidis Meglumine（Cat No.:I014697）is an oral medication approved for the treatment of transthyretin-mediated amyloidosis (ATTR), including both familial amyloid polyneuropathy (FAP) and transthyretin amyloid cardiomyopathy (ATTR-CM). It works by stabilizing the transthyretin (TTR) protein, preventing it from misfolding and forming amyloid deposits in tissues such as nerves and the heart. By inhibiting amyloid formation, Tafamidis Meglumine slows disease progression, improves neurological function, and enhances quality of life. Marketed under brand names like Vyndaqel and Vyndamax, it represents a significant advancement in managing these rare, progressive, and potentially fatal diseases.